<?xml version='1.0' encoding='utf-8'?>
<document id="27413118"><sentence text="Synergistic Potentiation of Cystic Fibrosis Transmembrane Conductance Regulator Gating by Two Chemically Distinct Potentiators, Ivacaftor (VX-770) and 5-Nitro-2-(3-Phenylpropylamino) Benzoate."><entity charOffset="139-145" id="DDI-PubMed.27413118.s1.e0" text="VX-770" /><entity charOffset="151-191" id="DDI-PubMed.27413118.s1.e1" text="5-Nitro-2-(3-Phenylpropylamino) Benzoate" /><pair ddi="false" e1="DDI-PubMed.27413118.s1.e0" e2="DDI-PubMed.27413118.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27413118.s1.e0" e2="DDI-PubMed.27413118.s1.e1" /></sentence><sentence text="Cystic fibrosis (CF) is caused by loss-of-function mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene encoding a phosphorylation-activated but ATP-gated chloride channel"><entity charOffset="183-191" id="DDI-PubMed.27413118.s2.e0" text="chloride" /></sentence><sentence text=" Previous studies suggested that VX-770 [ivacaftor, N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide], a CFTR potentiator now used in clinics, increases the open probability of CFTR by shifting the gating conformational changes to favor the open channel configuration" /><sentence text=" Recently the chloride channel blocker and CFTR potentiator 5-nitro-2-(3-phenylpropylamino) benzoate (NPPB) has been reported to enhance CFTR activity by a mechanism that exploits the ATP hydrolysis-driven, nonequilibrium gating mechanism unique to CFTR"><entity charOffset="14-22" id="DDI-PubMed.27413118.s4.e0" text="chloride" /><entity charOffset="60-100" id="DDI-PubMed.27413118.s4.e1" text="5-nitro-2-(3-phenylpropylamino) benzoate" /><entity charOffset="102-106" id="DDI-PubMed.27413118.s4.e2" text="NPPB" /><entity charOffset="184-187" id="DDI-PubMed.27413118.s4.e3" text="ATP" /><pair ddi="false" e1="DDI-PubMed.27413118.s4.e0" e2="DDI-PubMed.27413118.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27413118.s4.e0" e2="DDI-PubMed.27413118.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27413118.s4.e0" e2="DDI-PubMed.27413118.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27413118.s4.e0" e2="DDI-PubMed.27413118.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27413118.s4.e1" e2="DDI-PubMed.27413118.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27413118.s4.e1" e2="DDI-PubMed.27413118.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27413118.s4.e1" e2="DDI-PubMed.27413118.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27413118.s4.e2" e2="DDI-PubMed.27413118.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27413118.s4.e2" e2="DDI-PubMed.27413118.s4.e3" /></sentence><sentence text=" Surprisingly however, NPPB increased the activity of nonhydrolytic G551D-CFTR, the third most common disease-associated mutation"><entity charOffset="23-25" id="DDI-PubMed.27413118.s5.e0" text="NPPB" /></sentence><sentence text=" Here, we further investigated the mechanism of NPPB's effects on CFTR gating by assessing its interaction with well-studied VX-770"><entity charOffset="48-51" id="DDI-PubMed.27413118.s6.e0" text="NPPB" /></sentence><sentence text=" Interestingly, once G551D-CFTR was maximally potentiated by VX-770, NPPB further increased its activity"><entity charOffset="69-72" id="DDI-PubMed.27413118.s7.e0" text="NPPB" /></sentence><sentence text=" However, quantitative analysis of this drug-drug interaction suggests that this pharmacologic synergism is not due to independent actions of NPPB and VX-770 on CFTR gating; instead, our data support a dependent mechanism involving two distinct binding sites"><entity charOffset="142-145" id="DDI-PubMed.27413118.s8.e0" text="NPPB" /></sentence><sentence text=" This latter idea is further supported by the observation that the locked-open time of a hydrolysis-deficient mutant K1250A was shortened by NPPB but prolonged by VX-770"><entity charOffset="141-144" id="DDI-PubMed.27413118.s9.e0" text="NPPB" /></sentence><sentence text=" In addition, the effectiveness of NPPB, but not of VX-770, was greatly diminished in a mutant whose second nucleotide-binding domain was completely removed"><entity charOffset="35-38" id="DDI-PubMed.27413118.s10.e0" text="NPPB" /></sentence><sentence text=" Interpreting these results under the framework of current understanding of CFTR gating not only reveals insights into the mechanism of action for different CFTR potentiators but also brings us one step forward to a more complete schematic for CFTR gating" /><sentence text="" /></document>